Image 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif by Chen Chen (6544)

“…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca²⁺ concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”

WCESP (2 mg/ml) decreases <i>V</i>. <i>cholerae</i> cell-surface hydrophobicity. by Daniel B. Pederson (604306)

Decreased production of IL-12p70 and IL-23 in response to LPS+R848 stimulation in frail old individuals. by Nathalie Compté (418458)

Botulinum toxin A (3.5 U/kg) decreases dural extravasation in IoNC injured rats. by Boris Filipović (336089)

Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung. by Mi-Ran Lee (664596)

Genomic inactivation of the <i>PIWI</i> gene in <i>L. infantum</i> and <i>L. major</i> strains leads to a decrease in amastigote growth and disease pathology. by Prasad K. Padmanabhan (85254)

Archazolid decreases the activity and expression of cathepsin B in endothelial cells. by Betty Luong (5738027)

Neutrophils adhered to the apical surface of polarized-MDCK cells augment AdV entry without decreasing the TER. by Poornima L. N. Kotha (701665)

Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA₁/LPA₃ antagonist. by Masahiko Kanehira (183764)

“…CFU-F colonies initiated from the treated cells (passage 5, 100 cells) were counted after 15 days of normal culture. …”

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. by Da-eun Nam (18927946)

Diabetic wounds show increased amounts of vessel leakage and decreased pericyte coverage. by Uzoagu A. Okonkwo (8754933)

<i>In vivo</i> silencing (RNAi) of pairing-dependent lincRNAs decreases the number of <i>S</i>. <i>mansoni</i> adult worms recovered from infected mice. by Gilbert O. Silveira (7376819)

A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

“…<i>eIF4α</i> was used as an internal control. Values represent means ± SE from three independent experiments. <b>(C)</b> The mutant CLCuMuV carrying C4^R13A (CLCuMuV-C4^R13A), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”

Infection decreases short chain phospholipids in the intestines of <i>V</i>. <i>cholerae</i>-infected flies. by Audrey S. Vanhove (4090594)

The mean values of correctly memorized foreground characters and users’ SDNN in different background line orientations. by Yanqun Huang (7487657)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”